Commentary: Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis

Neurosurgery. 2023 Oct 1;93(4):e92. doi: 10.1227/neu.0000000000002524. Epub 2023 May 15.

Authors

Jens Blobner^{1

2}, Joerg-Christian Tonn^{1

2}

Affiliations

¹ Department of Neurosurgery, LMU University Hospital, Ludwig Maximilians University (LMU), Munich , Germany.
² German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg , Germany.

PMID: 37186882
DOI: 10.1227/neu.0000000000002524

No abstract available

MeSH terms

Brain Neoplasms* / genetics
Brain Neoplasms* / metabolism
Glioma* / genetics
Glioma* / metabolism
Histones / genetics
Humans
Isocitrate Dehydrogenase / genetics
Mutation / genetics
Prognosis

Substances

Histones
Isocitrate Dehydrogenase